Next Financial Group’s ImmunityBio IBRX Stock Holding History

Next Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-725	Closed	-$4K	–	2057
2016 Q4	$4K	Hold	725	–	–	﹤0.01%	1992
2016 Q3	$6K	Buy	+725	New	+$5.42K	﹤0.01%	1862

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Next Financial Group's IBRX Position: Q1 2017 in Review

Next Financial Group sold out of ImmunityBio (IBRX) in Q1 2017, closing a stake of 725 shares — an estimated $4K sold.

Next Financial Group first reported a position in IBRX in Q3 2016 and held it in 2 quarters. The position peaked at $6K in Q3 2016. 60 funds tracked by Wall St. Rank hold IBRX as of Q1 2017.

Next Financial Group reported no remaining ImmunityBio position as of Q1 2017 after selling out during the quarter.
Next Financial Group sold 725 ImmunityBio shares in Q1 2017, an estimated $4K.
Next Financial Group first reported a position in ImmunityBio in Q3 2016 and held it in 2 quarters.
Next Financial Group's ImmunityBio position peaked at $6K in Q3 2016.
60 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2017.

Based on Next Financial Group's 13F filing for Q1 2017, filed 8 May 2017.